Market Cap 243.56B
Revenue (ttm) 51.72B
Net Income (ttm) 11.94B
EPS (ttm) N/A
PE Ratio 13.01
Forward PE 12.67
Profit Margin 23.09%
Debt to Equity Ratio 0.73
Volume 2,389,700
Avg Vol 1,607,862
Day's Range N/A - N/A
Shares Out 2.11B
Stochastic %K 50%
Beta 0.62
Analysts Sell
Price Target $115.86

Company Profile

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 324 11 11
Fax: 41 61 324 80 01
Address:
Lichtstrasse 35, Basel, Switzerland
bullBearChop
bullBearChop Aug. 4 at 6:23 AM
$NVS Similar to AZN but with weaker chart. Needs time to base.
0 · Reply
SamCoyote
SamCoyote Aug. 3 at 10:29 PM
$NVS je me trompe ou avec le tarif de la mort à39% pour les produit Suisse va tout de même attaquer Novartis, même s'ils sont hors catégorie, exempté. Ça pourrait encore changer!
0 · Reply
onestudy
onestudy Aug. 1 at 7:13 PM
$CPHI There’s still tension in U.S.–China trade talks, but the Hainan Free Trade Port policy has already implemented a "Zero Tariff" policy for drugs and medical devices. 💡 Remember: $CPHI (China Pharma Holdings) is the only Hainan-based pharmaceutical company listed on a U.S. exchange — headquartered in Haikou, Hainan. Also, big pharma names are already present in the region: $MRK has a subsidiary located in Chengmai County, Hainan, and $NVS operates within the Bo’ao Lecheng International Medical Tourism Pilot Zone, also in Hainan. CPHI hasn’t really released any operational PR for almost a year — aside from the reverse split news in April. Honestly, it feels like there might be some kind of "deal talk" happening behind the scenes during this quiet period. I know it’s a big speculation to bring up, but those of you who’ve followed my DD on this company know I’ve been digging deep for a long time. Personally, I really believe there’s something going on — if you don’t mind me saying.
0 · Reply
Fingerlickengood
Fingerlickengood Aug. 1 at 5:14 PM
$CDXS $NVS Time to seal the deal with a US partnership! https://finance.yahoo.com/news/trump-unleashes-massive-tariffs-swiss-111107637.html
0 · Reply
Fingerlickengood
Fingerlickengood Aug. 1 at 4:51 PM
$CDXS $NVS This is going to be a Grandslam of a partnership! https://www.patientcareonline.com/view/fda-label-update-positions-inclisiran-as-first-line-monotherapy-for-hypercholesterolemia
0 · Reply
Quantumup
Quantumup Aug. 1 at 1:06 PM
Cantor⬆️ $APLS PT to $40 from $39, reiterated at an Overweight and said it thinks Empaveli C3G launch will go well. $NVS AZN $ALPMY $OCUL $EYPT REGN SRZN RHHBY Cantor said in its note: "We reiterate Overweight rating on $APLS as GA market is stabilizing and the launch in C3G/IC-MPGN is under way. C3G patients and nephrologists face a decision on how to treat their C3 glomerulopathy diagnosis: by inhibiting C3 (with Empaveli) .... or by inhibiting "FaCtOr B" (woozy emoji). Never mind in addition to actually reducing C3 deposits, Empaveli also has meaningfully better efficacy, a broader label, and absence of a hyperlipidemia warning found in Fabhalta's label. Consequently, we think Empaveli C3G launch will go well."
0 · Reply
CAN_2409
CAN_2409 Aug. 1 at 11:48 AM
Keytruda gives me 9 to 12 months to live. CAN-2409 immunotherapy Could give me 31.5 more months to live! My Oncologist's stopped giving me Keytruda and are giving me a better immunotherapy! Watching for any good news! Maybe from $MRK $NVS $PFE or $GSK ?
1 · Reply
Ro_Patel
Ro_Patel Jul. 31 at 3:24 PM
Results from SURPASS-CVOT show $LLY Mounjaro met its primary endpoint, showing non-inferior MACE-3 rates (CV death, heart attack, stroke) vs Trulicity Mounjaro: - 8% lower risk of CV events - 16% lower death rate Met pre-specified non-inferiority criteria Additional benefits (unadjusted for type-1 error): - Improved A1C, weight, renal function, and all-cause mortality - Largest/longest tirzepatide study to date: >13,000 patients, 4.5+ years Comparator: - $NVS Semaglutide (Ozempic/Wegovy) leads w/ 26% reduction in CV death, stroke, heart attack for T2D - Wegovy alone shows 20% reduction for people w/ obesity Lilly plans to submit these data to global regulatory authorities by YE25 & potentially supporting a label expansion w/ new cardiovascular benefits
1 · Reply
SparkyReturns
SparkyReturns Jul. 31 at 2:37 PM
$AZN Hey, just FYI. $NVS $MRK $AMGN
0 · Reply
Quantumup
Quantumup Jul. 30 at 2:52 PM
Raymond James assumed $SRRK Strong Buy⬆️PT=$53 was $49 &said "While expectations are elevated ahead of apitegromab approval this fall, we are confident in the value proposition of apitegromab in SMA, with plenty of long-term optionality in the pipeline." $RHHBY $BIIB $NVS $BHVN Raymond James: $SRRK's apitegromab, a mAb targeting latent myostatin, is progressing towards a Sept. 22 PDUFA date in spinal muscular atrophy (SMA), and while expectations are elevated in front of approval, apitegromab has the makings of a commercial winner—beyond SMA, $SRRK's myostatin programs have high value expansion opportunities in other neuromuscular indications, while potential out-licensing and partnerships in the obesity space can offer another source of near-term optionality.
0 · Reply
Latest News on NVS
Novartis AG (NVS) Q2 2025 Earnings Call Transcript

Jul 21, 2025, 2:50 AM EDT - 14 days ago

Novartis AG (NVS) Q2 2025 Earnings Call Transcript


Novartis raises outlook on strong second-quarter sales

Jul 17, 2025, 9:11 AM EDT - 18 days ago

Novartis raises outlook on strong second-quarter sales


Novartis cannot block generic version of Entresto, judge rules

Jul 16, 2025, 9:16 AM EDT - 19 days ago

Novartis cannot block generic version of Entresto, judge rules


Why Novartis Is Still A 'Buy' After 15% Surge

Jul 13, 2025, 10:45 AM EDT - 22 days ago

Why Novartis Is Still A 'Buy' After 15% Surge


Novartis loses bid to block US Entresto generic through 2026

Jul 11, 2025, 12:27 PM EDT - 24 days ago

Novartis loses bid to block US Entresto generic through 2026


Final Trades: Novartis, Sixth Street, Amazon and the IYF

Jun 26, 2025, 1:22 PM EDT - 5 weeks ago

Final Trades: Novartis, Sixth Street, Amazon and the IYF

AMZN IYF TSLY


Novartis completes acquisition of Regulus Therapeutics

Jun 25, 2025, 9:13 AM EDT - 5 weeks ago

Novartis completes acquisition of Regulus Therapeutics

RGLS


Novartis: A SWAN Worth Owning

Jun 25, 2025, 7:00 AM EDT - 5 weeks ago

Novartis: A SWAN Worth Owning


bullBearChop
bullBearChop Aug. 4 at 6:23 AM
$NVS Similar to AZN but with weaker chart. Needs time to base.
0 · Reply
SamCoyote
SamCoyote Aug. 3 at 10:29 PM
$NVS je me trompe ou avec le tarif de la mort à39% pour les produit Suisse va tout de même attaquer Novartis, même s'ils sont hors catégorie, exempté. Ça pourrait encore changer!
0 · Reply
onestudy
onestudy Aug. 1 at 7:13 PM
$CPHI There’s still tension in U.S.–China trade talks, but the Hainan Free Trade Port policy has already implemented a "Zero Tariff" policy for drugs and medical devices. 💡 Remember: $CPHI (China Pharma Holdings) is the only Hainan-based pharmaceutical company listed on a U.S. exchange — headquartered in Haikou, Hainan. Also, big pharma names are already present in the region: $MRK has a subsidiary located in Chengmai County, Hainan, and $NVS operates within the Bo’ao Lecheng International Medical Tourism Pilot Zone, also in Hainan. CPHI hasn’t really released any operational PR for almost a year — aside from the reverse split news in April. Honestly, it feels like there might be some kind of "deal talk" happening behind the scenes during this quiet period. I know it’s a big speculation to bring up, but those of you who’ve followed my DD on this company know I’ve been digging deep for a long time. Personally, I really believe there’s something going on — if you don’t mind me saying.
0 · Reply
Fingerlickengood
Fingerlickengood Aug. 1 at 5:14 PM
$CDXS $NVS Time to seal the deal with a US partnership! https://finance.yahoo.com/news/trump-unleashes-massive-tariffs-swiss-111107637.html
0 · Reply
Fingerlickengood
Fingerlickengood Aug. 1 at 4:51 PM
$CDXS $NVS This is going to be a Grandslam of a partnership! https://www.patientcareonline.com/view/fda-label-update-positions-inclisiran-as-first-line-monotherapy-for-hypercholesterolemia
0 · Reply
Quantumup
Quantumup Aug. 1 at 1:06 PM
Cantor⬆️ $APLS PT to $40 from $39, reiterated at an Overweight and said it thinks Empaveli C3G launch will go well. $NVS AZN $ALPMY $OCUL $EYPT REGN SRZN RHHBY Cantor said in its note: "We reiterate Overweight rating on $APLS as GA market is stabilizing and the launch in C3G/IC-MPGN is under way. C3G patients and nephrologists face a decision on how to treat their C3 glomerulopathy diagnosis: by inhibiting C3 (with Empaveli) .... or by inhibiting "FaCtOr B" (woozy emoji). Never mind in addition to actually reducing C3 deposits, Empaveli also has meaningfully better efficacy, a broader label, and absence of a hyperlipidemia warning found in Fabhalta's label. Consequently, we think Empaveli C3G launch will go well."
0 · Reply
CAN_2409
CAN_2409 Aug. 1 at 11:48 AM
Keytruda gives me 9 to 12 months to live. CAN-2409 immunotherapy Could give me 31.5 more months to live! My Oncologist's stopped giving me Keytruda and are giving me a better immunotherapy! Watching for any good news! Maybe from $MRK $NVS $PFE or $GSK ?
1 · Reply
Ro_Patel
Ro_Patel Jul. 31 at 3:24 PM
Results from SURPASS-CVOT show $LLY Mounjaro met its primary endpoint, showing non-inferior MACE-3 rates (CV death, heart attack, stroke) vs Trulicity Mounjaro: - 8% lower risk of CV events - 16% lower death rate Met pre-specified non-inferiority criteria Additional benefits (unadjusted for type-1 error): - Improved A1C, weight, renal function, and all-cause mortality - Largest/longest tirzepatide study to date: >13,000 patients, 4.5+ years Comparator: - $NVS Semaglutide (Ozempic/Wegovy) leads w/ 26% reduction in CV death, stroke, heart attack for T2D - Wegovy alone shows 20% reduction for people w/ obesity Lilly plans to submit these data to global regulatory authorities by YE25 & potentially supporting a label expansion w/ new cardiovascular benefits
1 · Reply
SparkyReturns
SparkyReturns Jul. 31 at 2:37 PM
$AZN Hey, just FYI. $NVS $MRK $AMGN
0 · Reply
Quantumup
Quantumup Jul. 30 at 2:52 PM
Raymond James assumed $SRRK Strong Buy⬆️PT=$53 was $49 &said "While expectations are elevated ahead of apitegromab approval this fall, we are confident in the value proposition of apitegromab in SMA, with plenty of long-term optionality in the pipeline." $RHHBY $BIIB $NVS $BHVN Raymond James: $SRRK's apitegromab, a mAb targeting latent myostatin, is progressing towards a Sept. 22 PDUFA date in spinal muscular atrophy (SMA), and while expectations are elevated in front of approval, apitegromab has the makings of a commercial winner—beyond SMA, $SRRK's myostatin programs have high value expansion opportunities in other neuromuscular indications, while potential out-licensing and partnerships in the obesity space can offer another source of near-term optionality.
0 · Reply
Bonso99
Bonso99 Jul. 30 at 10:16 AM
0 · Reply
Estimize
Estimize Jul. 30 at 10:00 AM
Wall St is expecting 2.25 EPS for $NVS Q3 [Reporting 10/28 BMO] http://www.estimize.com/intro/nvs?chart=historical&metric_name=eps&utm_cont
0 · Reply
TalkMarkets
TalkMarkets Jul. 29 at 8:09 PM
3 International #Dividend Stocks With High Yields $NVS $UL $OTEX https://talkmarkets.com/content/stocks--equities/3-international-dividend-stocks-with-high-yields?post=512201
0 · Reply
Quantumup
Quantumup Jul. 29 at 7:23 PM
Jefferies⬆️ $KNSA PT to $54 from $45 & reiterated at a Buy after they caught up w/ mgmt. following $KNSA's 2Q25 earnings print. $REGN $AMGN $NVS Jefferies said in its note, "Q2 carries over the success in Q1 with another 'beat & raise' - 2025FY guidance increased from previous $590-605M to $625-640M, supported by growth in new/ repeat Rxers, average DoT and penetration into both target 2+ RP and first RP pop. Monthly KLP-387 dev on track, aiming for '28-29 launch. Co has $308M cash/ expects to remain cash flow positive on annual basis. We raise our PT to $54 from previous $45."
0 · Reply
zoey1970
zoey1970 Jul. 29 at 1:46 PM
$REGN An article you may find of interest "Circuit Design Brings New Possibilities for Restoring Vision in Retinal Disease Patients" A patient diagnosed with a degenerative retinal disease once faced a future of fading sight and growing uncertainty. Medical technology offered some hope, but existing devices found it difficult to recreate the complex way the eye and brain communicate. Recently, engineers have developed a new kind of circuit that works much like the brain’s own cells—able to remember and respond to electrical signals in a way that could help restore vision more naturally. This small, carefully designed component, called a memristor emulator, is now showing potential to improve retinal implants, making them smarter and more adaptive to the needs of patients. This progress brings medical devices closer to matching the delicate inner workings of the human eye Read more here if interested https://neuromorphiccore.ai/circuit-design-brings-new-possibilities-for-restoring-vision-in-retinal-disease-patients/ $OCUL $JNJ $NVS $COO
0 · Reply
Quantumup
Quantumup Jul. 29 at 12:51 PM
Cantor reiterated $APLS Overweight/$39 after Apellis announced Empaveli received sNDA approval in patients 12 years or older with C3G or primary IC-MPGN." $NVS $AZN Cantor added, "The label specifically includes eGFR data (showing stability) with a time series insert that's not present in Fabhalta label. C3G/IC-MPGN patients can use commercially approved pump or Empaveli injector, twice-weekly subQ administration compared to twice daily oral Fabhalta. C3G is potentially a $1B+ opportunity for Apellis in the U.S. In 2025E, we model~$4.5M (FactSet $12.4M) revenue and in 2026E ~$106M (FactSet $114.2M). We think Novartis' Fabhalta launch in C3G provides a nice proof of commercial opportunity, and Empaveli can and likely will be used in a wider population (IC-MPGN, post-transplant, adolescents)."
0 · Reply
Expert24
Expert24 Jul. 24 at 4:41 PM
$NCNA $TNFA both will blast off today😎 $PFE $NVS $MRK
1 · Reply
whylieineedMorleysmoney
whylieineedMorleysmoney Jul. 23 at 6:20 PM
$IOVA So who is buying the only real Melanoma treatment in the world oh and lung soon which might even be better. $MRK $PFE $NVS
0 · Reply
whylieineedMorleysmoney
whylieineedMorleysmoney Jul. 23 at 1:46 PM
$AMRN $PFE $MRK $NVS looks like Amarin could be a takeover target smoke some Morleys if you got ‘em 🚬 🚬 🚬 upgrading to a Morleys 3 smokes play could be be four if we find out more.
1 · Reply
Fingerlickengood
Fingerlickengood Jul. 23 at 1:43 PM
0 · Reply
Quantumup
Quantumup Jul. 22 at 6:44 PM
Piper Sandler y'day reiterated $CRNX Overweight-$97-Top Pick after🗣️w/ a Leading ENDO—he Tx's a couple hundred acromegaly pts—plans to offer PALSONIFY immediately to almost all pts— +was impressed w/ atumelnant's Ph1b/2a Cushing's data/is +VE on this opp $BCHMY $IPSEY $NVS $CORT $XERS Piper Sandler in its note to investors said:
1 · Reply
Fingerlickengood
Fingerlickengood Jul. 22 at 3:07 PM
$CDXS $GILD $NVS ..this is great news!
2 · Reply